Immutep Limited Enters Into Clinical Trial Collaboration

  • Jan 07, 2019 AEDT
  • Team Kalkine
Immutep Limited Enters Into Clinical Trial Collaboration

To test eftilagimod alpha as part of a cancer peptide vaccine discovered by artificial intelligence new clinical trial collaboration with CYTLIMIC has been performed. With their cancer vaccine product candidate including efti, it builds on Immutep Limited (ASX: IMM)’s longstanding relationship with CYTLIMIC which recently reported encouraging data in Phase I clinical trial. 

For its lead product candidate eftilagimod alpha as part of a cancer vaccine the company is happy to reveal that it has entered into a clinical trial collaboration agreement, a supply agreement and a service agreement with CYTLIMIC Inc. To collaborate on clinical trials to evaluate efti as part of a therapeutic cancer vaccine, the agreements enable the two parties containing CYTLIMIC’s innovative cancer peptide vaccine, called CYT001.

The trials will be conducted by and are under the control of CYTLIMIC who will fully fund all development costs. Under the collaboration agreement, the company will receive an upfront payment of US$500,000, and upon the achievement of milestones by CYTLIMIC it is eligible to receive up to US$4.5M in milestone payments. Efti is being evaluated in clinical studies in a combination, this therapeutic cancer vaccine with efti is the third example.

In combination with either chemotherapy, Immutep retains complete exclusivity over its patent rights, exactly covering its clinical development programs and those it is conducting in combination with its other collaboration partners evaluating IMP321. Immutep has entered into a supply agreement for use in the clinical development and commercialization of the vaccine to provide efti to CYTLIMIC for the manufacture of CYT001, in addition to the collaboration agreement. During the development and commercialization of CYT001, the parties have also entered into a service agreement where the company will provide technical support services to CYTLIMIC.

Immutep CEO Marc Voigt said, commenting on the agreements, that ‘as part of an innovative cancer vaccine that has potential as a new therapy, they are very excited to be working alongside CYTLIMIC to help evaluate efti. It is now being evaluated as part of three different combination therapy types, following the agreements with CYTLIMIC.’

Immutep Limited is trading at 9.677% higher at $0.034; the stock has performed 34.78% higher over the past 12 months. The market cap at current price is $103.68 million as at January 07, 2018.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

 

All pictures are copyright to their respective owner(s).Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK